1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cost and healthcare utilization in relapsed/refractory diffuse large B-cell lymphoma: A real-world analysis of Medicare beneficiaries receiving chimeric antigen receptor T-cell vs. autologous and allogeneic hematopoietic cell transplants
    Meeting Abstract

    Mohammadi, I.; Purdum, A. G.; Wong, A. C.; Schroeder, A.; Kilgore, K. M.; Shah, G. L.
    Blood (2020)

    Fulltext@MSK | Save
  • R-CHOP versus R-Bendamustine with or without rituximab maintenance in newly diagnosed follicular lymphoma patients with high SUV at baseline PET
    Meeting Abstract

    Mondello, P.; Strati, P.; Merryman, R. W.; Joffe, E.; Ruella, M.; Seshan, V.; St Pierre, F.; Major, A.; Pophali, P.; Fiasconaro, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Successful treatment of mature T-cell lymphoma with allogeneic stem cell transplantation: The largest multicenter retrospective analysis
    Meeting Abstract

    Mehta-Shah, N.; Kommalapati, A.; Teja, S.; Cashen, A. F.; Dahi, P. B.; Sauter, C. S.; Moskowitz, A. J.; Jacobsen, E. D.; William, B. M.; Ozga, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • End of treatment peripheral blood T-cell receptor gene rearrangement evaluation for minimal residual disease evaluation in peripheral T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Fehniger, T. A.; Jacobsen, E. D.; Peterson, K.; Kahl, B. S.; Bartlett, N. L.; Cashen, A. F.; Ghobadi, A.; Fischer, A.; Reagan, B.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Interim positron emission tomography (iPET) assessed using Deauville score for patients with follicular lymphoma receiving first-line chemoimmunotherapy
    Meeting Abstract

    Merryman, R. W.; Spilberg, G.; Mondello, P.; Redd, R. A.; Taranto, E.; Ahmed, G.; Jeter, E.; Chase, M.; Salles, G.; Zelenetz, A. D.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Prognostic value of circulating tumor DNA (ctDNA) in autologous stem cell graft and post-transplant plasma samples among patients with diffuse large B-cell lymphoma
    Meeting Abstract

    Merryman, R. W.; Redd, R. A.; Taranto, E.; Ahmed, G.; Jeter, E.; McHugh, K. M.; Brown, J. R.; Crombie, J.; Davids, M. S.; Fisher, D. C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A once daily, oral, triple combination of BTK inhibitor, mTOR inhibitor and IMiD for treatment of relapsed/refractory Richter's transformation and de novo diffuse large B-cell lymphoma
    Meeting Abstract

    Mato, A. R.; Schuster, S. J.; Foss, F. M.; Isufi, I.; Kothari, S. K.; Ding, W.; Brander, D. M.; Sitlinger, A.; Rosenthal, A. C.; Leis, J. F.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Cardiovascular and metabolic risk in patients with chronic myeloid leukemia in chronic phase receiving first-line BCR-ABL1 tyrosine kinase inhibitors in the United States: Baseline and six-month follow-up results from a prospective real-world observational study
    Meeting Abstract

    Mauro, M. J.; Oehler, V. G.; Thompson, J. E.; McCloskey, J. K.; Heinrich, M. C.; Dakhil, S. R.; DeGutis, I.; Tabano, D.; Khan, W.; Moslehi, J. J.
    Blood (2020)

    Fulltext@MSK | Save
  • LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: Results from the phase 1/2 BRUIN study
    Meeting Abstract

    Mato, A. R.; Pagel, J. M.; Coombs, C. C.; Shah, N. N.; Lamanna, N.; Lech-Marańda, E.; Eyre, T. A.; Woyach, J. A.; Wierda, W. G.; Cheah, C. Y.; more...
    Blood (2020)

    Fulltext@MSK | Save